Report Overview:
Oral anorexiant drugs are medications designed to suppress appetite and reduce food intake, aiding in weight loss for individuals who are overweight or obese. These drugs typically act on the central nervous system, either by stimulating the release of certain neurotransmitters like norepinephrine and dopamine, which can create a feeling of fullness, or by blocking the reuptake of these chemicals, prolonging their appetitesuppressing effects. Commonly prescribed oral anorexiants include phentermine, diethylpropion, and lorcaserin. They are often used in conjunction with lifestyle modifications such as diet and exercise to enhance weight loss results. However, these medications can have side effects such as increased heart rate, elevated blood pressure, insomnia, and potential for abuse or dependency, and they are usually recommended for short-term use under medical supervision.
This report provides a deep insight into the global Oral Anorexiant Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Oral Anorexiant Drug market size was estimated at USD 752 million in 2024 and is projected to reach USD 1198.57 million by 2032, exhibiting a CAGR of 6.00% during the forecast period.
North America Oral Anorexiant Drug market size was estimated at USD 216.62 million in 2024, at a CAGR of 5.14% during the forecast period of 2024 through 2032.
CAGR of 6.00% (2025 – 2032)
By Types:
Catecholamines
Serotonin
By Applications: Hospitals
Key players include:
•Akrimax Pharmaceuticals
•Janssen Ortho
•Roche Pharmaceuticals
•Teva Pharmaceuticals
•Arena Pharmaceuticals
•Abbott Pharmaceuticals
•Including or Excluding key companies relevant to your analysis.
